ConqueringCancerCalls for TheCytomXFactor

Xceptional vision and Xtraordinary therapies to outsmart cancer, transform lives

We're on it.

CytomX is a different kind of clinical-stage biopharmaceutical company—intent on revolutionizing the way we treat cancer. Our distinctive ProbodyTM therapeutics are progressing through the clinic with the promise of unlocking the full potential of more potent, less toxic anti-cancer medications. Our ultimate goal is to bring more life-changing treatment options to more patients.

Diverse clinical-stage pipeline

With three Probody programs in the clinic and two additional clinical stage programs by the end of 2018, our aim is to transform cancer treatment and patients’ lives.

Learn More

Xceptional people wanted

We’re building something special—and are looking for passionate individuals who want to make a meaningful difference in lives and the world.

Do you have the CytomX Factor?

Learn More

A smarter approach to treating cancer

Our Probody therapeutics are designed to selectively bind to cancer cells—helping spare the patient from unwanted side effects.

Learn More
Parental antibody
Substrate linker Links mask to antibody; stable in vivo in circulation, but cleaved by tumor-specific proteases
Masking peptide Blocks antigen binding until released when substrate is cleaved, producing a fully active antibody
Proteases Dysregulated activity of specific proteases in diseased tissue cleaves substrate to enable Probody therapeutic binding

"We’re focusing on how to make cancer drugs safer and by doing so, can potentially make those cancer drugs more effective."

—Dan Hostetter